Correlation Between Bristol Myers and Mereo BioPharma

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Mereo BioPharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Mereo BioPharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Mereo BioPharma Group, you can compare the effects of market volatilities on Bristol Myers and Mereo BioPharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Mereo BioPharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Mereo BioPharma.

Diversification Opportunities for Bristol Myers and Mereo BioPharma

-0.46

Correlation Coefficient

Bristol Myers  Mereo BioPharma

Very good diversification

The 3 months correlation between Bristol and Mereo is -0.46. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Mereo BioPharma Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mereo BioPharma Group and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Mereo BioPharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mereo BioPharma Group has no effect on the direction of Bristol Myers i.e., Bristol Myers and Mereo BioPharma go up and down completely randomly.

Pair Corralation between Bristol Myers and Mereo BioPharma

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.45 times more return on investment than Mereo BioPharma. However, Bristol Myers Squibb is 2.2 times less risky than Mereo BioPharma. It trades about 0.09 of its potential returns per unit of risk. Mereo BioPharma Group is currently generating about -0.18 per unit of risk. If you would invest  5,545  in Bristol Myers Squibb on December 28, 2024 and sell it today you would earn a total of  457.00  from holding Bristol Myers Squibb or generate 8.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Bristol Myers Squibb  vs.  Mereo BioPharma Group

Bristol Myers Squibb

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal primary indicators, Bristol Myers may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Mereo BioPharma Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Bristol Myers and Mereo BioPharma

The main advantage of trading using opposite Bristol Myers and Mereo BioPharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Mereo BioPharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will offset losses from the drop in Mereo BioPharma's long position.

The idea behind Bristol Myers Squibb and Mereo BioPharma Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.